Literature DB >> 19441132

Progression of ataxia in patients with Machado-Joseph disease.

Marcondes C França1, Anelyssa D'Abreu, Anamarli Nucci, Fernando Cendes, Iscia Lopes-Cendes.   

Abstract

Although ataxia is the most distressing manifestation of Machado-Joseph disease (MJD), little is known about its natural history. Therefore, we prospectively followed a cohort of patients with MJD for 13 months to characterize the progression of ataxia and identify its contributory factors. The international cooperative ataxia rating scale (ICARS) was used to estimate severity of ataxia at baseline and at follow-up. Thirty-four patients were enrolled in the study, 22 of whom were men. Mean age at onset of the disease was 34.7 years and length of expanded CAG repeat was 66. Mean ICARS scores at baseline was 37.6 and at follow-up was 42.7 (P < 0.001). Multivariate analysis did not find significant association of progression of disease and age at disease onset, length of expanded (CAG), or duration of disease. 2009 Movement Disorder Society.

Entities:  

Mesh:

Year:  2009        PMID: 19441132     DOI: 10.1002/mds.22627

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  15 in total

1.  The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.

Authors:  H Jacobi; P Bauer; P Giunti; R Labrum; M G Sweeney; P Charles; A Dürr; C Marelli; C Globas; C Linnemann; L Schöls; M Rakowicz; R Rola; E Zdzienicka; T Schmitz-Hübsch; R Fancellu; C Mariotti; C Tomasello; L Baliko; B Melegh; A Filla; C Rinaldi; B P van de Warrenburg; C C P Verstappen; S Szymanski; J Berciano; J Infante; D Timmann; S Boesch; S Hering; C Depondt; M Pandolfo; J-S Kang; S Ratzka; J Schulz; S Tezenas du Montcel; T Klockgether
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

2.  Spinocerebellar ataxia type 3/Machado-Joseph disease starting before adolescence.

Authors:  Karina Carvalho Donis; Jonas Alex Morales Saute; Ana Carolina Krum-Santos; Gabriel Vasata Furtado; Eduardo Preusser Mattos; Maria Luiza Saraiva-Pereira; Vanessa Leotti Torman; Laura Bannach Jardim
Journal:  Neurogenetics       Date:  2016-01-16       Impact factor: 2.660

Review 3.  Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials.

Authors:  Jonas Alex Morales Saute; Karina Carvalho Donis; Carmen Serrano-Munuera; David Genis; Luís Torres Ramirez; Pilar Mazzetti; Luis Velázquez Pérez; Pilar Latorre; Jorge Sequeiros; Antoni Matilla-Dueñas; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

4.  Progression rate of neurological deficits in a 10-year cohort of SCA3 patients.

Authors:  Laura Bannach Jardim; Lisiane Hauser; Christian Kieling; Jonas Alex Morales Saute; Renan Xavier; Carlos Roberto Mello Rieder; Thais Lampert Monte; Suzi Camey; Vanessa Bielefeld Leotti Torman
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

Review 5.  Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets.

Authors:  Marta Daniela Costa; Patrícia Maciel
Journal:  Cell Mol Life Sci       Date:  2022-05-03       Impact factor: 9.261

Review 6.  Rating scales and biomarkers for CAG-repeat spinocerebellar ataxias: Implications for therapy development.

Authors:  Meng-Ling Chen; Chih-Chun Lin; Liana S Rosenthal; Puneet Opal; Sheng-Han Kuo
Journal:  J Neurol Sci       Date:  2021-04-01       Impact factor: 3.181

7.  Nerve growth factor for the treatment of spinocerebellar ataxia type 3: an open-label study.

Authors:  Song Tan; Rui-Hao Wang; Hui-Xia Niu; Chang-He Shi; Cheng-Yuan Mao; Rui Zhang; Bo Song; Shi-Lei Sun; Xin-Jing Liu; Hai-Man Hou; Yu-Tao Liu; Yuan Gao; Hui Fang; Xiang-Dong Kong; Yu-Ming Xu
Journal:  Chin Med J (Engl)       Date:  2015-02-05       Impact factor: 2.628

Review 8.  Degenerative Ataxias: challenges in clinical research.

Authors:  Sub H Subramony
Journal:  Ann Clin Transl Neurol       Date:  2016-11-17       Impact factor: 4.511

9.  Gender Differences in Non-sex Linked Disorders: Insights From Huntington's Disease.

Authors:  Daniel Zielonka; Barbara Stawinska-Witoszynska
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

10.  CAG repeat length does not associate with the rate of cerebellar degeneration in spinocerebellar ataxia type 3.

Authors:  Shang-Ran Huang; Yu-Te Wu; Chii-Wen Jao; Bing-Wen Soong; Jiing-Feng Lirng; Hsiu-Mei Wu; Po-Shan Wang
Journal:  Neuroimage Clin       Date:  2016-11-10       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.